Finance

Lists
FDMT:NASDAQ
4D Molecular Therapeutics Inc
$13.75
+4.40%
(+0.58) 1D
Sep 14, 11:15:54 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for FDMT...
Open
$13.64
High
$13.98
Low
$13.43
Mkt. cap
759.61M
Avg. vol.
930.98K
Volume
266.91K
52-wk high
$16.91
52-wk low
$6.47
EPS
-$2.76
Beta
2.74
Shares outstanding
55.24M
No. of employees
196
Open
$13.64
High
$13.98
Low
$13.43
Mkt. cap
759.61M
Avg. vol.
930.98K
Volume
266.91K
52-wk high
$16.91
52-wk low
$6.47
EPS
-$2.76
Beta
2.74
Shares outstanding
55.24M
No. of employees
196
News stories
From web sources and news partners
About 4D Molecular Therapeutics Inc
CEO-
Employees196
Founded2013
HeadquartersEmeryville, California, United States
SectorBiotechnology
Website4dmoleculartherapeutics.com
Analyst ratings
Based on 9 analysts giving stock ratings to FDMT in the past 3 months
Strong buy
Buy
8
Hold
1
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for FDMT in the last 3 months.
Highest
Current $13.75
$37.00 (+169.09%)
Average
$30.29 (+120.29%)
Lowest
$20.00 (+45.45%)
Analyst
Recommendation
Action
Price target
Projected
Date
Joshua Schimmer
Cantor Fitzgerald
Buy
Upgraded
$20.00
+45.5%
09/14/2026
Eliana Merle
Barclays
Buy
Maintained
$28.00
+103.6%
09/11/2026
Judah Frommer
Morgan Stanley
Hold
Reiterated
-
-
08/17/2026
Daniel Giraldo
Bank of America Securities
Buy
Maintained
-
-
08/14/2026
Lisa Walter
RBC Capital
Buy
Reiterated
$35.00
+154.5%
08/14/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
$36.00
+161.8%
08/14/2026
Unknown Analyst
B. Riley Securities
Buy
Initiated
$37.00
+169.1%
07/31/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
$23.00
+67.3%
07/20/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$33.00
+140%
07/20/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$26.00
+89.1%
05/08/2026
Faisal Khurshid
Jefferies
Buy
Initiated
$21.00
+52.7%
03/30/2026
Last report
Aug 13, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$1.04 / -$1.02
-2.29%miss
Revenue / Est. (USD)
3.78M / 2.72M
+39.26%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
90.00K
85.09M
3.05M
3.78M
Cost of goods sold
47.24M
57.51M
64.98M
68.28M
Cost of revenue
47.24M
57.51M
64.98M
68.28M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.84M
12.77M
11.69M
12.52M
Operating expense
11.84M
12.77M
11.69M
12.52M
Total operating expenses
59.08M
70.28M
76.67M
80.81M
Operating income
-58.98M
14.82M
-73.62M
-77.02M
Other non operating income
-21.00K
-22.00K
-4.00K
-166.00K
EBT including unusual items
-56.88M
19.40M
-68.76M
-72.94M
EBT excluding unusual items
-54.68M
19.50M
-68.76M
-72.94M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-56.88M
19.40M
-68.76M
-72.94M
Net profit margin
-63,195.56%
22.80%
-2,256.65%
-1,929.01%
Earnings per share
-1.01
0.43
-1.01
-1.04
Interest and investment income
4.33M
4.70M
4.86M
4.26M
Interest expense
-
-
-
-
Net interest expenses
4.33M
4.70M
4.86M
4.26M
Depreciation and amortization charges
-
-
-
-
EBITDA
-57.72M
16.03M
-72.35M
-75.74M
Gain or loss from assets sale
-
-
-
43.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps